Literature DB >> 1774280

Inability of cephalothin testing to predict cefprozil susceptibility.

J Fung-Tomc1, T Stickle, C Doyle, E Huczko, R E Kessler.   

Abstract

The 30-micrograms cefprozil disk and the cephalosporin class (30-micrograms cephalothin) disk were compared for their abilities to predict cefprozil susceptibility by agar disk diffusion testing. High error (5.02% major and 14.11% minor) rates were encountered with the cephalothin disk and were most frequently observed for Escherichia coli and Enterococcus faecalis. The cefprozil disks resulted in rates of 0.05% very major, 0% major, and 3.72% minor errors. Thus, the 30-micrograms cefprozil disk is more desirable for predicting cefprozil susceptibility.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1774280      PMCID： PMC270395          DOI： 10.1128/jcm.29.11.2643-2647.1991

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  11 in total

1.  Phase I study of multiple-dose cefprozil and comparison with cefaclor.

Authors:  R H Barbhaiya; U A Shukla; C R Gleason; W C Shyu; R B Wilber; R R Martin; K A Pittman
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

2.  In vitro activity and beta-lactamase stability of the oral cephalosporin BMY-28100.

Authors:  M Hiraoka; S Masuyoshi; K Tomatsu; M Inoue; S Mitsuhashi
Journal:  Eur J Clin Microbiol       Date:  1987-10       Impact factor: 3.267

3.  Susceptibility tests of anaerobic bacteria: statistical and clinical considerations.

Authors:  C M Metzler; R M DeHaan
Journal:  J Infect Dis       Date:  1974-12       Impact factor: 5.226

4.  Comparative antibacterial activity of the new oral cephalosporin BMY-28100.

Authors:  F H Kayser
Journal:  Eur J Clin Microbiol       Date:  1987-06       Impact factor: 3.267

5.  Comparative antibacterial activity of a new oral cephalosporin, BMY-28100.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

6.  In vitro activity of BMY 28100, a new oral cephalosporin.

Authors:  J Steele; B Edwards; J Rissing
Journal:  Eur J Clin Microbiol       Date:  1987-02       Impact factor: 3.267

7.  Disk diffusion susceptibility testing and broth microdilution quality control guidelines for BMY-28100, a new orally administered cephalosporin.

Authors:  R N Jones; A L Barry
Journal:  J Clin Microbiol       Date:  1987-11       Impact factor: 5.948

8.  Comparative in vitro activity of the new oral cephalosporin BMY-28100.

Authors:  K E Aldridge; D D Schiro; C V Sanders
Journal:  Eur J Clin Microbiol       Date:  1987-04       Impact factor: 3.267

9.  In vitro and in vivo evaluations of BMY-28100, a new oral cephalosporin.

Authors:  K Tomatsu; S Ando; S Masuyoshi; S Kondo; M Hirano; T Miyaki; H Kawaguchi
Journal:  J Antibiot (Tokyo)       Date:  1987-08       Impact factor: 2.649

10.  BMY-28100, a new oral cephalosporin: antimicrobial activity against nearly 7,000 recent clinical isolates, comparative potency with other oral agents, and activity against beta-lactamase producing isolates.

Authors:  R N Jones; A L Barry
Journal:  Diagn Microbiol Infect Dis       Date:  1988-01       Impact factor: 2.803
View more
  1 in total

1.  Antibacterial activities of cefprozil compared with those of 13 oral cephems and 3 macrolides.

Authors:  J C Fung-Tomc; E Huczko; T Stickle; B Minassian; B Kolek; K Denbleyker; D Bonner; R Kessler
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.